Teva présente les données de phase 3 et OLE d'ecopipam soutenant l'examen prioritaire de la FDA pour le syndrome de Tourette pédiatrique

With ecopipam's application currently under FDA Priority Review, Teva Pharmaceuticals has released a consolidated dataset that QA and regulatory leads at pediatric CNS manufacturing sites should begin tracking now. The data, presented at the International Congress of Parkinson's Disease and Movement Disorders in Seoul (October 4–8, 2026), span a pooled post hoc analysis, an interim open-label extension readout, and subgroup findings on comorbid psychiatric conditions.

The pooled post hoc analysis drew on 292 patients across Phase 2b and Phase 3 trials. Within eight weeks of initiating ecopipam, 69.8% of participants achieved a clinically meaningful improvement on the Yale Global Tic Severity Scale Total Tic Score (YGTSS-TTS), defined as a reduction of 25% or greater. Somnolence and headache were the most commonly reported adverse events, concentrated in that same early-exposure window.

Long-term durability data come from an interim analysis of an ongoing 36-month open-label extension study. Of 118 patients with a median treatment exposure of 14.9 months, ecopipam maintained clinically meaningful tic suppression through 18 months, with a mean YGTSS-TTS reduction of 45.6%. No new safety signals were identified. Commonly reported adverse events at this stage included nasopharyngitis, upper respiratory tract infection, anxiety, diarrhea, influenza, pyrexia, and insomnia.

A separate post hoc subgroup analysis of 216 Phase 3 participants evaluated the effect of co-occurring psychiatric conditions, including ADHD, OCD, anxiety, and depression. Tic severity reductions and overall tolerability profiles were consistent between patients with at least one co-occurring condition (n=129) and those without (n=87), a finding that broadens the eligible population profile relevant to labeling and post-approval pharmacovigilance planning.

Ecopipam is a first-in-class selective D1 dopamine receptor antagonist, mechanistically distinct from all currently available Tourette syndrome therapies. If approved, it would represent the first new treatment for the indication in over a decade and the first novel mechanism of action in more than 50 years, a profile that carries distinct formulation, stability, and process validation considerations for any site preparing to manufacture at commercial scale.

The 36-month open-label extension study remains ongoing, and the full dataset at study completion will be the next measurable checkpoint for regulatory and manufacturing readiness planning.

Source: Teva Pharmaceuticals via GlobeNewswire, October 2, 2026.